Radiation and Immune Checkpoints Blockade in Metastatic Non-Small Cell Lung Cancer (NSCLC)
Radiation and Immune Checkpoints Blockade in Metastatic Non-Small Cell Lung Cancer (NSCLC)
Sponsor: Weill Cornell
Enrolling: Male and Female Patients
IRB Number: AAAS2593
U.S. Govt. ID: NCT03168464
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test whether local radiotherapy combined with Ipilimumab is safe. The study will try to find out if it can help patients with metastatic non-small cell lung cancer better than treatment with Ipilimumab and Nivolumab alone.
This study is closed
Investigator
Brian Henick, MD
Do You Qualify?
Are you age 18 or older? Yes No
Have you been diagnosed with metastatic non-small cell lung cancer? Yes No
Have your received at least one prior treatment for your disease? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE